Abstract
Designs for clinical trials have undergone little change in the past 30 years. Nonetheless, conventional designs have numerous inadequacies. Because it fails to use all available information accumulated during the trial and typically has an insufficient sample size, the 3+3 phase 1 design is often unlikely to select the correct dose implied in the 3+3 algorithm. The design fails to account for covariates, thus assuming, despite evidence to the contrary, that dose is the only determinant of toxicity. It does not monitor response, thus failing to recognize the phase 2 aspects of phase 1 trials and the phase 1 aspects of phase 2 trials; rather these features are often addressed in an ad hoc fashion. Phase 2 trials similarly ignore the realities of medical practice. Thus, although patients are interested in frequent data analyses, standard designs discourage these because of the connection between p-value and trial design and the desire to maintain a specified final p-value. In addition to being inadequately adaptive, phase 2 designs are frequently concerned with only a single outcome. Here we propose remedies for the shortcomings noted above. Such solutions are based on the Bayesian paradigm.
Key Words
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Thall P, Lee SJ. Practical model-based dose-finding in phase 1 clinical trials: methods based on toxicity. Int J Gynecol Cancer 2003;13:251–261.
Estey EH, Thall PF. New designs for phase 2 clinical trials. Blood 2003;102:442–448.
Berry DA. Statistical innovations in cancer research. In: Holland J et al., eds. Cancer Medicine, 6th ed. London: BC Decker, 2003;465–478.
Berger JO, Berry DA. Statistical analysis and the illusion of objectivity. Am Scientist 1988;76:159–165.
O’Quigley J, Pepe M, Fisher L. Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics 1990;46:33–48.
Piantadosi S, Fisher JD, Grossman S. Practical implementation of a modified continual reassessment method for dose-finding trials. Cancer Chemother Pharmcol 1998;41:429–436.
Moller S. An extension of the continual reassessment method using a preliminary up-and-down design in a dose-finding study in cancer patints, in order to investigate a greater range of doses. Stat Med 1995;14:911–922.
Rogatko A, Babb JS, Wang H, Slifker MJ, Hudes GR. Patient characteristics compete with dose as predictors of acute treatment toxicity in early phase clinical trials. Clin Cancer Res 2004;10:4645–4651.
Thall P, Estey E, Sung H-G. A new statistical method for dose-finding based on efficacy and toxicity in early phase clinical trials. Invest New Drugs 1999;17:155–167.
Simon R. Optimal two-stage designs for phase II clinical trials. Controlled Clin Trials 1989;10:1–10.
Thall P, Simon R. Incorporating historical control data in planning phase 2 clinical trials. Stat Med 1990; 9:215–228.
Thall PF, Estey E. A Bayesian strategy for screening cancer treatments prior to Phase II clinical evaluation. Stat Med 1993;12:1197–1211.
Inoue LYT, Thall PF, Berry DA. Seamlessly expanding a randomized phase II trial to phase III. Biometrics 2002;58:823–831.
Giles FJ, Kantarijan HM, Cortes JE, et al. Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia. J Clin Oncol 2003;21:1722–1727.
Thall PF, Sung H-G, Estey EH. Selecting therapeutic strategies based on efficacy and death in multi-course clinical trials. J Am Statist Assoc 2002;97:29–39.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Humana Press Inc., Totowa, NJ
About this chapter
Cite this chapter
Estey, E. (2007). New Designs for Clinical Trials. In: Karp, J.E. (eds) Acute Myelogenous Leukemia. Contemporary Hematology. Humana Press. https://doi.org/10.1007/978-1-59745-322-6_20
Download citation
DOI: https://doi.org/10.1007/978-1-59745-322-6_20
Publisher Name: Humana Press
Print ISBN: 978-1-58829-621-4
Online ISBN: 978-1-59745-322-6
eBook Packages: MedicineMedicine (R0)